Jasper Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10–K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: February 28, 2025 | JASPER THERAPEUTICS, INC. | |
|---|---|---|
| By: | /s/ Ronald Martell | |
| Ronald Martell Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Ronald Martell | President, Chief Executive Officer and Director | February 28, 2025 |
| Ronald Martell | (Principal Executive Officer) | |
| /s/ Herb Cross | Chief Financial Officer | February 28, 2025 |
| Herb Cross | (Principal Accounting and Financial Officer) | |
| /s/ Thomas G. Wiggans | Chairperson of the Board | February 28, 2025 |
| Thomas G. Wiggans | ||
| /s/ Scott Brun, M.D. | Director | February 28, 2025 |
| Scott Brun, M.D. | ||
| /s/ Vishal Kapoor | Director | February 28, 2025 |
| Vishal Kapoor | ||
| /s/ Svetlana Lucas, Ph.D. | Director | February 28, 2025 |
| Svetlana Lucas, Ph.D. | ||
| /s/ Christian W. Nolet | Director | February 28, 2025 |
| Christian W. Nolet | ||
| /s/ Judith Shizuru, M.D., Ph.D. | Director | February 28, 2025 |
| Judith Shizuru, M.D., Ph.D. | ||
| /s/ Kurt von Emster | Director | February 28, 2025 |
| Kurt von Emster | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.